INTRODUCTION
Several laboratories have provided evidence for the existence of a multigene family of human leukocyte interferons (LeIFs or IFN-a). Allen and Fantes (1) have demonstrated that microheterogeneity in preparations of leukocyte interferon from Namalwa cells can be ascribed to at least five homologous proteins of different amino acid sequence, and therefore to different structural genes. Using a cloned LeIF cDNA as hybridization probe, Nagata £t a}_. (2) have identified eight distinct LeIF chromosome segments in a genomic DNA library of a single individual. Moreover, we have isolated at least eight LeIF cDNA species (3) cloned from polyadenylated mRNA of myeloblastoid cells stimulated for interferon production.
The functional specificities of the interferons which are expressed during the viral-induced state have yet to be determined. We have recently shown that one bacterially synthesized human LeIF we termed type A was sufficient to protect squirrel monkeys jm vivo from lethal encephalomyocarditis virus infection (4) . In this report we describe the construction of a plasmid which directs the expression of a novel LeIF, LeIF B, and present evidence that LeIFs A and B have target cell specificities distinct from each other and from interferon isolated from pooled human leukocytes.
MATERIALS AND METHODS
Enzymes and DNA Preparations. Plasmid DNA was prepared by a standard cleared lysate procedure (5) and purified by Bio-Rad Agarose A-50 column chromatography. DNA restriction fragments were purified by electroelution from 6 percent polyacrylamide gels. Small amounts of plasmid DNA were isolated by a published procedure (6) . T4 DNA ligase was used in 20 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 10 mM dithiothreitol, 0.5 mM ATP. Restriction endonuclease Eco RI was a gift from Dr. Pat Greene and was used in 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5mM MgCl 2 , 0.02 percent NP40. Pst I was provided by Dr. Herb Heyneker and was used in 6mM Tris-HCl (pH 7.5), 50 mM NaCl, 6 mM MgCl 2 , 6 mM 8-mercaptoethanol. All other restriction enzymes were from New England Biolabs and were used according to manufacturer's recommendations.
Identification and characterization of a plasmid containing full length LeIF B cDNA. The preparation of a cDNA library using polyadenylated RNA from Sendai virus-induced KG-1 cells has been described in an earlier publication (4). Plasmid pL4 was hybridized to 32 P-labelled synthetic deoxyoligonucleotides potentially complimentary to LeIF mRNA and to a 263 base pair Bgi II fragment from pLelF A under conditions previously described (4) . The DNA sequence of the Pst I insert of pL4 was determined by the method of Maxam and Gilbert (7) and by dideoxy chain termination (8) after subcloning Sau 3a fragments into bacteriophage M13 mp 7 (9) . Construction of expression piasmids. A pre-interferon expression plasmid was constructed by ligating 100 ng of Pst I digested pNCV (4) with approximately a 30 fold molar excess of purified cDNA insert in a 20 pi reaction containing 5 units T4 DNA ligase. The entire ligation mix was used to transform competent E_. col i 294 (10) . Transformants were selected on Luria plates (11) containing 5 yg ml tetracycline.
The assembly of the direct expression plasmid pLelF B7 is depicted in Figures 2 and 3 . One hundred micrograms of pL4 (pBR322 containing LeIF B cDNA inserted at the Pst I site) were treated with Pst I and Xba I and electrophoresed on a 6 percent polyacrylamide gel. Two resultant fragments were electroeluted: a 343 base pair (bp) segment containing tne 5' end of the cDNA gene sequence up to the Xba I site, and the larger (>700 bp) segment containing the latter portion of the gene and untranslated 3' sequences. One half of the former was treated with Sau 3a and Eco RI and the 105 bp product eluted. The other half was treated with Eco RI alone, and the 134 bp product eluted. The LeIF B gene was reassembled in a pair of ligations. The Sau 3a-Eco RI fragment and Eco Rl-Xba I fragment were ligated in 100 yl total volume containing 20 units T4 ligase at room temperature for three hours. The reaction was terminated by heating to 65°C for 10 minutes, and the mix was treated with Xba I and Bgl II to preclude polymers through the Xba I and Sau 3a sticky ends, respectively. The desired 239 bp fragment was purified on a 6 percent polyacrylamide gel and ligated with the remainder of the gene (Xba I-Pst I) using the same conditions. The reaction mixture was treated with Pst^ I and Bgl II and the resultant ~1040 bp fragment was isolated. A 330 bp Hind III-Sau 3a DNA segment containing the ^. coli trp promoter-operator, the trp leader ribosome binding site, and an ATG start codon followed by the first two codons of leukocyte IF type A and 8 was isolated from pLelF A25 (see text). In the final assembly, equimolar amounts of the ~1040 bp LeIF B gene, the trp promoter, and the pBR322 vector segments were used in a 20 yl reaction containing 5 units T4 DNA 1igase.
Preparation of bacterial extracts and interferon assays. Bacterial growth conditions and lysis procedures have been published elsewhere (12) . Interferon titers in crude bacterial extracts were determined by plaque reduction as described in the legends to Tables 1 and 2 
RESULTS AND DISCUSSION
Our initial approach in identifying cloned human leukocyte interferon cDNA was to select recombinant plasmios which hybridized to P-labelled cDNA extended from deoxyoligonucleotide primers potentially complimentary to interferon mRNA (4). The primer sequences were designed from the limited LeIF protein sequence information then available (w. Levy, J. Shively, and S. Pestka, unpublished results). Positive cDNA hybridization probes were prepared using template mRNA from leukocytes induced for interferon production; this mRNA yielded high titers of interferon when translated in Xenopus laevis oocytes. Control cDNA probes were prepared using mRNA from uninduced leukocytes. Clone pL4 was one of thirty which hybridized strongly to the positive cDNA probe but not to the control. In an earlier publication (4) we gave the details of this approach and also reported the isolation of the plasmid pL39 which contained a full length human leukocyte interferon cONA species which we designated type A. Streuli et al. (13) have also identified and sequenced a cloned LeIF cDNA species, designated IFN-a2(13), corresponding to LeIF A. pL4 was one of several plasmids which also hybridized strongly to a 32 P-labelled 263 base pair JJgJ II fragment from pL39 (data not shown); however, the restriction patterns of the two cloned cDNAs were quite dissimilar. Pst I restriction of pL4 released an inserted cDNA fragment greater than 1000 bp in length. The insert contained two Eco RI sites, no Bgl II sites, two Pvu II sites separated by almost 400 bp, and a unique Xba I site. This was also unlike the restriction pattern of the cloned leukocyte IF cDNA described by Nagata, et^ a±. (14) and subsequently denoted as IFN-al (13). The DNA sequence of the Pst I insert of pL4 was determined; it was homologous to, but distinct from, the cDNA sequence of LeIF A. We called the interferon species encoded in pL4 LeIF B. We have maintained the single letter designations A-H to refer to the eight distinct LeIF cDNA species which have been isolated in our laboratory (3). Since linkage relationships of the LeIF chromosomal genes are under active investigation (2,3) and will provide a logical basis for classification using the IFN-a nomenclature, we feel it more appropriate to postpone alpha-numeric assignment until the individual sequences have been shown to correspond to distinct genetic loci.
The sequence of the cloned LeIF B cDNA is presented in Figure 1 IFN-al (13,14) . Our own sequencing differs by only one nucleotide in the coding region and predicts a valine at amino acid 114 rather than alanine (16) . When the sequences are aligned as shown, one hundred and fifteen of the predicted amino acids are identical for all three species. LeIF A is anomalous in having only 165 amino acids; types B, D, and all other LeIF cDNA species sequenced in our laboratory have 166 amino acids (3). A potentially significant site of variation among the three LeIFs occurs at amino acid positions 98-101. The nucleotide sequence of LeIF B cDNA has an apparent insertion which alters the reading frame for four codons, when a deleted residue restores the sequence homology. The predicted cysteine residue which is thereby displaced is one of the four highly conserved cysteines which are involved in disulfide bridges (17) .
Expression of pre-LelF B. Since the cDNA of LeIF B included the intact signal peptide sequence, we sought to express the LeIF B pre-interferon gene in _E. col i using the plasmid pNCV. pNCV is a generalized expression vector which contains the E^. col i trp promoter-operator region and parts of the anthranilate synthetase coding region preceding a unique £s_t I site (4). The Psjt I cDNA insert from pL4 was ligated into the Pst I site of pNCV; plasmid DNA from transformants was restricted with Eco RI to determine whether the orientation was in the direction of transcription from the trp promoter. The interferon titers from extracts of £. coli carrying one such hybrid plasmid, pLe-prelF B4, are shown in Table 1 . In pNCV, expression presumably occurs via re-initiation of translation at the first methionine of the signal peptide. The measured activity may be due to intact preinterferon polypeptides, or perhaps to some bacterial proteolytic processing into mature LeIF (4). Initially, we assessed the antiviral activity of the extracts using Sindbis virus on human WISH cells; in that system, activity from pLe-prelF B4 was approximately fourfold lower than activity from the analogous pLe-prelF A2. When VSV was used as the challenge, however, the apparent antiviral activity from pLe-prelF A2 decreased significantly.
Expression plan and results. As shown in Figure 1 , the first fourteen bases of the coding region of mature LeIF B are identical with those of LeIF A. This region encompasses a Sau 3a site between codons 2 and 3. We therefore planned to isolate a fragment from a plasmid which directs the expression of LeIF A which would contain the first few nucleotides of LeIF B already adjoining a suitable promoter-operator, and Bacterial cultures were grown and extracted by a published procedure (12) . The human amnion WISH cell line was used for the CPE inhibition assay (18) using Sindbis or Vesicular Stomatitis Virus as challenge. Activities given are the average of three or more independent evaluations. use this to directly express LeIF B. The plasmid pLelF A25 contains an Eco RI fragment which includes the /£. coli trp promoter, operator, and trp leader ribosome binding site preceding an ATG initiation triplet in front of the initial cysteine codon of LeIF A (4). A Hind III-Sau 3a digestion of 30 yg of pLelF A25 yielded approximately 2 pg of a 330 bp fragment comprising the trp promoter, the LeIF B start, and 29 bp of pBR322. Figure 2 presents a map of the Pst I insert of pL4 showing salient restriction sites. The existence of multiple Sau 3a sites within the coding region precludes a one step isolation of the gene without resorting to partial digests. We elected to isolate and reassemble the LeIF B gene stepwise, purifying each component from extraneous restriction and ligation products. We worked from 100 pg starting material (purified pL4) so that each step could be easily visualized on polyacrylamide gels.
The assembly of the LeIF B expression plasmid is depicted in Figure 3 . In the last three part ligation, 500 ng of the large fragment from a Hind Ill-Pst^ I digest of pBR322 was ligated with 50 ng of the 330 bp Hind III-Sau 3a trp promoter fragment and 150 ng of the ~104O bp Sau 3a-Pst I segment bearing LeIF B cDNA. The ligation mix was used to transform E. coli 294 (10) . Nine colonies arose on Luria plates containing 5 pg Characterization of LeIF B. In Table 1 , the activities oDtained from extracts of E. coli 294/pLeIF B7 are compared with those of identically prepared extracts of E^ coli 294/pLeIF A25. As the activities from extracts of the pre-interferon clones had suggested, yields of LeIF B measured against Sindbis virus were repeatedly twofold lower than yields of LeIF A. The construction of pLelF B7 necessitated that both the promoter system and the distance between the ribosome binding site and the initiation codon should be the same as in pLelF A25. Nevertheless, since the determinations were made with unpurified material, it was not possible to assess whether LeIF A was synthesized more efficiently by the bacteria, was more stable in lysed preparations, or had a higher specific activity in our routine assay system. In this assay, activities are determined by titration against an interferon standard supplied by the NIH. When vesicular stomatitis virus was used as the challenge, the activities of the extracts of 294/pLeIF A25 and 294/pLeIF B7 were equivalent.
We also compared target cell specificities of LeIF B with LeIF A and with authentic LeIF partially purified from human leukocytes. These data are presented in Table 2 . As the CPE inhibition assay had shown, the same dilution of crude extracts of E_. coli 294/pLeIF A25 and ^. col i 294/pLeIF B7 gave 50 percent plaque reduction of human WISH cells challenged by VSV. However, several striking differences between the protection of types A and B are evident. LeIF A is 200 times more active than LeIF B on hamster kidney cells; it is nearly ten times more active on mouse L cells. The authentic interferon, which is presumably a mixture of many related human LeIFs, some or all of which may be glycosylated, does not protect mouse L-cells at all at the concentrations we could test. In our cDNA clone bank, LeIF A is the predominant species (3); however, its apparent activity on mouse cells is not reflected in Table 2 Cultures of ^. col i 294/pLeIF A25 and j^. coli/pLelF B7 were grown and lysed by a published procedure (12) . A crude lysate of ^. coli 294/pBR322 prepared identically was included as a control. Cell monolayers were pretreated 18 hours with serial dilutions of the lysates or with a leukocyte interferon standard preparation from Watfley Institute of Molecular Medicine. VSV was absorbed 60 min. at room temperature after which the inoculum was removed and the cells covered with 0.7 percent Noble agar in MEM, 2 percent fetal calf serum, 100 units/ml penicillin, and 100 ug/ml streptomycin. Plates were incubated overnight at 37°C; monolayers were fixed, stained, and scored for plaque forming units. The sample dilution which gave 50 percent plaque reduction was calculated from duplicate assays of multiple dilutions. Table values are normalized such that this level protection of human WISH cells is 100 percent. Actual dilutions which gave 50 percent reduction were 1:5000 for both LeIF A and LeIF B, and 1:500,000 for LeIF standard. the activity from the mixed LeIF preparation. The activity of the mixed LeIFs on rabbit kidney (RK-13) cells might also predict that one or more other LeIF species will be highly active on those cells. Streuli, et al. (13) reported differing antiviral activities of two bacterially synthesized human leukocyte interferons, IFN-al and IFN-a2, on human and bovine cell lines. These LeIFs are nearly identical to our LeIFs D and A, respectively. The differing antiviral effects of the bacterially synthesized LeIFs demonstrate that the activities can be ascribed to inherent structural properties of the proteins. Animal studies are ay to determine the significance of these oroperties iji yjvo.
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